Indica Labs and Paige have formed a nonexclusive partnership to integrate Paige’s diagnostic artificial intelligence (AI) models into Indica’s anatomic pathology workflow management software, HALO AP.
Indica's integration includes Paige’s pancancer AI application that was developed using Paige’s foundation model technology, according to the companies. HALO AP users will be able to execute Paige's AI applications and view results directly within the HALO AP image management system. Integration rollout is expected within the next few months.
Paige recently announced a strategic initiative to bring artificial general intelligence (AGI) to pathology and oncology, as well as transition its diagnostic AI applications from being exclusive to the Paige platform to a standalone solution compatible with other digital pathology platforms.
In other news, Ibex Medical Analytics reported a recent study that pathologists using the company's Prostate AI software were 58% more efficient at signing out cases. The retrospective study was conducted through Ibex's collaboration with Quest Diagnostics and Prostate AI's integration with the Proscia Concentriq enterprise pathology platform.
Quest Diagnostics, through its AmeriPath and Dermpath Diagnostics subspecialty pathology businesses, employs over 400 pathologists within its nationwide network of clinical laboratories, according to Ibex. Pathology workflows are evolving, said Dr. Darren Wheeler, vice president of pathology and medical services at Quest in the statement.
Ibex also said that its prostate, breast, and gastric AI solutions secured In Vitro Diagnostic Regulation (IVDR) certification under new EU regulations.
